Enhanced Liver Fibrosis (ELF) Test Availability

Enhanced Liver Fibrosis (ELF) Test Availability
  • Now available, the ELFTM Test is the first and only prognostic blood test granted De Novo marketing authorization to assess disease progression in NASH patients.
  • The ELF Test is now easily accessible at more than 4,250 patient testing locations nationwide.

Siemens Healthineers‘ Enhanced Liver Fibrosis (ELF) Test is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF Test is exclusively available through partnerships with LabCorp and Quest Diagnostics, providing more than 4,250 locations across the country. This is the first time the test is commercially available in the U.S., following De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in August 2021.

By clicking Submit you consent to the processing of your above given personal data by the Siemens Healthineers company referred to under Corporate Information and for the purpose described above. Further information concerning the processing of your data can be found in the Data Privacy Policy. You are aware that you can partially or completely revoke this consent at any time for the future. Please declare your revocation to the contact address given in the Corporate Information and sent it to us via the following e-mail address: dataprivacy.func@siemens-healthineers.com